Caroline Seymour

Charalambos (Babis) Andreadis, MD, MSCE, discusses the use of CAR T-cell therapy in patients with DLBCL and the associated toxicities with each product, as well as other promising therapies in the paradigm.

Peter O’Donnell, MD, discusses the integration of immunotherapy in the treatment paradigm of advanced bladder cancer and its potential role as combination therapy.

Radhakrishnan Ramchandren, MD, discusses the treatment landscape in Hodgkin and T-cell lymphoma and the results of the North American subgroup analysis of the ECHELON-1 trial.

Jay Yang, MD, explains that drug development is not as simple as identifying a molecular target and matching inhibitor.

Rami S. Komrokji, MD, reflects on the diverse acute myeloid leukemia treatment landscape and touches on the prognostic importance of biomarkers.

Walter M. Stadler, MD, gives an overview of the current prostate cancer landscape and discussed future directions.

Jubilee Brown, MD, Brown explains the value of genetic testing for patients predisposed to and diagnosed with ovarian cancer.

Patrick M. Forde, MBBCh, discusses the advances in early-stage non–small cell lung cancer, emphasizing neoadjuvant and adjuvant immunotherapy trials in stage I, II, and III disease.

Erlene Seymour, MD, discusses novel therapies as well as their potential applications in the treatment paradigm of chronic lymphocytic leukemia.

Sara A. Hurvitz, MD, discusses de-escalation strategies in early-stage HER2-positive breast cancer and novel HER2-targeted therapies in development.

Abhinav Deol, MD, discusses the presentation and prevalence of idiopathic thrombocytopenic purpura in addition to the current and emerging therapeutic strategies that are used to manage the disease.

Josephine L. Feliciano, MD, discusses established and emerging therapeutic developments for patients with non–small cell lung cancer with less common driver mutations.

Robert L. Coleman, MD, FACOG, FACS, discusses the evolution of treatment for patients with ovarian cancer, the therapies with the most potential, and the importance of classification schemes in directing treatment in recurrent disease.

Dennis J. Slamon, MD, PhD, discusses how the MONALEESA-3 results have shifted the understanding of therapy placement in women with HR-positive, HER2-negative advanced breast cancer.

Adam F. Brufsky, MD, PhD, discusses the differences between biosimilars and biologics, incentives for biosimilar use, and investigational agents on the horizon.

Bradley McGregor, MD, discusses the impact of combination therapies on the treatment landscape and highly anticipated studies in renal cell carcinoma.

Kenneth H. Shain, MD, PhD, discusses the evolution of treatment for patients with newly diagnosed multiple myeloma and how physicians are leveraging data with chimeric antigen receptor T-cell therapy and minimal residual disease negativity to improve outcomes.

Frederick L. Locke, MD, discusses the expansion of CAR T-cell therapy in patients with lymphomas following the 2017 approval of axicabtagene ciloleucel and remaining research questions with the therapy.

Andrew T. Kuykendall, MD, discusses the presentation of myeloproliferative neoplasms, novel agents in development, and the overall outlook of these diseases.

Benjamin P. Levy, MD, discusses established and emerging biomarkers that could have predictive value with immunotherapy.

Rachid Baz, MD, discusses the ARROW, ELOQUENT-3, and OPTIMISMM studies and highlights others that are demonstrating equally impressive response rates in patients with relapsed/refractory multiple myeloma.

Carlos Becerra, MD, discusses sequencing strategies, immunotherapy, and practice-changing clinical trials in the field of pancreatic cancer.

Celeste Bello, MD, discusses the latest advances in the treatment of patients with follicular lymphoma.

Jarushka Naidoo, MBBCh, discusses the toxicities associated with the use of immunotherapy in oncology, optimal methods of managing them, and the growing body of knowledge on why they occur.

Thomas Herzog, MD, traces the therapeutic evolution of frontline treatment for patients with ovarian cancer.

Julie R. Brahmer, MD, provides an overview of the landscape of metastatic non–small cell lung cancer, specifically addressing the combination immunotherapy studies with the greatest impact.

Matthew J. Ellis, MD, PhD, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive breast cancer.

Maryam Nemati Shafaee, MD, discusses the pivotal trials in breast cancer that were reported at the 2018 ASCO Annual Meeting.

D. Ross Camidge, MD, PhD, discusses the use of immunotherapy in patients with non–small cell lung cancer.

Dustin M. Walters, MD, provides perspective on the treatment landscape of stage III non–small cell lung cancer.